GRANATA BIO CORP
GenericsGRANATA BIO CORP is a generic drug manufacturer with 1 FDA-approved products.
GRANATA BIO CORP's Key Drugs
GRANATA BIO CORP's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
GRANATA BIO CORP's Recent FDA Approvals
New NDA/BLA approvals for GRANATA BIO CORP over the last two years — novel drugs only, excluding generics and label supplements.
GRANATA BIO CORP's Therapeutic Areas
Disease areas where GRANATA BIO CORP has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
GRANATA BIO CORP Pipeline Snapshot
Active clinical trials for GRANATA BIO CORP across all therapeutic areas, from ClinicalTrials.gov.
Phase 3 Readout Calendar Pro
1 Phase 3 trial with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1988-12-20
- Latest
- 2025-08-15
- Applications
- 1